MTOR and ovarian serous carcinoma: The PI3K/AKT/mTOR pathway is unregulated in approximately 70% of OC patients while activated MAPK pathway was more frequently expressed in low-grade (81%) as compared with high-grade ovarian serous carcinomas (41%) (53–55).